Dermatology News and Research

Latest Dermatology News and Research

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Indoor tanning beds can cause skin cancer

Back to school means new classes, clothes and schedules, including a heavy calendar of social events. Unfortunately, many young adults, particularly young women, head to indoor tanning salons in preparation for high school and college dances in the fall.

7 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Apricus Bio raises over $9.3 million in securities offering

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company has closed its previously announced securities offering, raising over $9.3 million in gross proceeds. Apricus Bio intends to use the proceeds from this offering for product and technology development and general corporate purposes. Dawson James Securities acted as the exclusive placement agent for the offering.

5 Oct 2010

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

IRIDEX Corporation today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery devices. The EndoProbe is an intraocular laser delivery device used during vitreoretinal surgery for the treatment of multiple disorders including: diabetic retinopathy, retinal detachments and vitreous hemorrhage. IRIDEX distributes products in Japan through their partner, TOMEY Corporation.

5 Oct 2010

NextGen Ambulatory EHR version 5.6 SP1 achieves ONC-ATCB 2011/2012 certification

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today that NextGen® Ambulatory EHR version 5.6 SP1 is 2011/2012 compliant and was certified as a Complete EHR on September 30, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the applicable eligible provider certification criteria adopted by the Secretary of Health and Human Services.

4 Oct 2010

Encorium announces extension of expiration date for pending rights offering

Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has extended the expiration date for its pending rights offering from September 30, 2010 to October 15, 2010. The subscription rights may now be exercised at any time prior to 5:00 p.m. ET on Friday, October 15, 2010.

1 Oct 2010

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Boston Medical Center (BMC) has been awarded a four year, $5.7 million grant from the National Heart, Lung and Blood Institute (NHLBI) for investigators from Boston University School of Medicine (BUSM) to create the Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities.

1 Oct 2010

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Results from a randomized, double-blinded, placebo-controlled, multicentred study just published in the Journal of Drugs in Dermatology shows that treating Actinic Keratoses (AK) with imiquimod 3.75% (Zyclara®) following cryotherapy was more effective than cryotherapy alone in reducing total AK lesion count and achieving complete clearance of AK.

30 Sep 2010

Apricus Biosciences prices securities offering

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that it has entered into agreements with selected investors to sell up to 1,728,882 Units at a price per Unit of $5.40, for aggregate gross proceeds of approximately $9.3 million.

29 Sep 2010

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

As teens and twenty-somethings returned to school this month, many obsessed about their appearance, especially those with moderate to severe acne. A new screening test might save the day.

29 Sep 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

Valeant Pharmaceuticals completes merger of Biovail Corporation

Valeant Pharmaceuticals International, Inc. today announced the completion of the merger of Biovail Corporation and Valeant Pharmaceuticals International following the approval of the merger by shareholders of both companies.

28 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private placement. The notes are additional notes constituting a part of the same series as the $750 million aggregate principal amount of 7-3/4% senior notes due 2018 issued on August 20, 2010.

24 Sep 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

Dermatology News and Research

Latest Dermatology News and Research

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

Indoor tanning beds can cause skin cancer

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Apricus Bio raises over $9.3 million in securities offering

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

NextGen Ambulatory EHR version 5.6 SP1 achieves ONC-ATCB 2011/2012 certification

Encorium announces extension of expiration date for pending rights offering

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Apricus Biosciences prices securities offering

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Valeant Pharmaceuticals completes merger of Biovail Corporation

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

FDA approves OZURDEX implant for uveitis treatment

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in